Target unmet needs Lysogene focuses on neurodegenerative lysosomal storage disorders in children, presenting a clear opportunity to explore partnerships or trials with academic centers, patient advocacy groups, and CROs specializing in pediatric gene therapies.

Strategic partnerships Existing collaboration with Sarepta Therapeutics suggests receptivity to co-development or licensing arrangements; sales outreach can emphasize joint development, manufacturing, or distribution partnerships in gene therapy.

Funding readiness With approximately $30M in funding raised and a near $0-1M annual revenue profile, there may be opportunities to engage investors and strategic buyers about earlier-stage deals, grant-backed programs, or milestone-based collaborations.

Clinical execution Lysogene’s end-to-end experience from discovery to regulatory review implies strong project management capabilities; positioning as a partner for clinical trial support, regulatory consulting, orCMC optimization could resonate with biotechs lacking in-house depth.

Patient-centric value Founded by a founder with a personal patient story, there is a narrative and impact angle to engage with patient communities, hospitals, and payer discussions to build support for access programs and reimbursement strategies for pediatric gene therapies.